Back to Journals » Therapeutics and Clinical Risk Management » Volume 12

Treatment cost of narcolepsy with cataplexy in Central Europe

Authors Maresova P, Novotny M, Klímová B, Kuča K

Received 16 August 2016

Accepted for publication 16 September 2016

Published 18 November 2016 Volume 2016:12 Pages 1709—1715

DOI https://doi.org/10.2147/TCRM.S119888

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Lucy Goodman

Peer reviewer comments 2

Editor who approved publication: Professor Garry Walsh

Petra Maresova,1 Michal Novotny,2,3 Blanka Klímová,4 Kamil Kuča3,5
1Department of Economics, Faculty of Informatics and Management, 2Department of Chemistry, Faculty of Science, University of Hradec Králové, 3Biomedical Research Center, University Hospital Hradec Králové, 4Department of Applied Linguistics, Faculty of Informatics and Management, 5Faculty of Informatics and Management, University of Hradec Králové, Hradec Králové, Czech Republic


Background: Narcolepsy is a lifelong, rare neurological sleep disorder characterized by chronic, excessive attacks of daytime sleepiness. This disease is often extremely incapacitating, interfering with every aspect of life, in work and social settings.
Objective: The purpose of this study is to specify the treatment costs of patients in the Central Europe (Czech Republic), while the attention is mainly paid to the drugs that were fully or partially covered by public health insurance. Furthermore, concomitant therapy is also evaluated, since it incurs a certain financial burden for patients and their family members. On the basis of the calculated costs, impact on the public budget is evaluated.
Patients and methods: This study monitors the direct costs of the drugs for 13 patients, who represent ~1.3% of the total number of diagnosed patients in the Czech Republic, and evaluates the costs associated with their treatment during the period from January 9, 2011 to April 23, 2013.
Results: Most of the treatment costs (~80%) were covered by publicly available sources. This finding is also true for the concomitant therapy of comorbidities. Additional payments for the drugs constitute about 20% of the total costs.

Keywords: cataplexy, cost, narcolepsy, orphan drug, rare disease, sodium oxybate

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Bilingualism as a strategy to delay the onset of Alzheimer’s disease

Klimova B, Valis M, Kuca K

Clinical Interventions in Aging 2017, 12:1731-1737

Published Date: 19 October 2017

J-pouch versus Roux-en-Y reconstruction after gastrectomy: functional assessment and quality of life (randomized trial)

Zonca P, Maly T, Ihnat P, Peteja M, Kraft O, Kuca K

OncoTargets and Therapy 2017, 10:13-19

Published Date: 16 December 2016

Costs of inguinal hernia repair associated with using different medical devices in the Czech Republic

Marešová P, Peteja M, Lerch M, Zonca P, Kuca K

Therapeutics and Clinical Risk Management 2016, 12:1593-1597

Published Date: 26 October 2016

Prediction of population with Alzheimer's disease in the European Union using a system dynamics model

Tomaskova H, Kuhnova J, Cimler R, Dolezal O, Kuca K

Neuropsychiatric Disease and Treatment 2016, 12:1589-1598

Published Date: 30 June 2016

The influence of methods of bariatric surgery for treatment of type 2 diabetes mellitus

Bužga M, Maresova P, Seidlerová A, Zonča P, Holéczy P, Kuča K

Therapeutics and Clinical Risk Management 2016, 12:599-605

Published Date: 15 April 2016

Assistive technologies for managing language disorders in dementia

Klimova B, Maresova P, Kuca K

Neuropsychiatric Disease and Treatment 2016, 12:533-540

Published Date: 29 February 2016

The potential of medical device industry in technological and economical context

Maresova P, Penhaker M, Selamat A, Kuca K

Therapeutics and Clinical Risk Management 2015, 11:1505-1514

Published Date: 3 October 2015

Alzheimer's disease and its treatment costs: case study in the Czech Republic

Mohelska H, Maresova P, Valis M, Kuca K

Neuropsychiatric Disease and Treatment 2015, 11:2349-2354

Published Date: 11 September 2015

Alzheimer’s disease and language impairments: social intervention and medical treatment

Klimova B, Maresova P, Valis M, Hort J, Kuca K

Clinical Interventions in Aging 2015, 10:1401-1408

Published Date: 27 August 2015